Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12622000421730p
Ethics application status
Submitted, not yet approved
Date submitted
28/01/2022
Date registered
14/03/2022
Date last updated
14/03/2022
Date data sharing statement initially provided
14/03/2022
Type of registration
Prospectively registered

Titles & IDs
Public title
Effects of polyherbal mouthwash versus 0.2% Chlorhexidine mouthwash on patients for dental plaque, gingivitis, and gingival bleeding in Faisalabad, Pakistan: A randomized comparative clinical trial..
Scientific title
Effects of polyherbal mouthwash versus 0.2% Chlorhexidine mouthwash on patients for dental plaque, gingivitis, and gingival bleeding in Faisalabad, Pakistan: A randomized comparative clinical trial.
Secondary ID [1] 306009 0
None
Universal Trial Number (UTN)
U1111-1273-7146
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Dental plaque 324647 0
Gingivitis 325070 0
Gingival bleeding 325071 0
Condition category
Condition code
Oral and Gastrointestinal 322099 322099 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The subjects in intervention arm shall receive herbal mouthwash, the product under test. Subject will be counseled to take 10ml of the mouthwash and rinse mouth with it for 1 minute, after brushing teeth. The frequency will be once daily at night for 30 days. The herbal mouthwash will contain essential oil extracts of clove, cardamom, cinnamon, peppermint leaves and fennel, and aqueous extracts of neem and miswak. The adherence shall be monitored by counting the returned of unused mouthwash bottles.
Intervention code [1] 322415 0
Treatment: Other
Comparator / control treatment
The subjects in intervention arm shall receive 0.2% chlorhexidine gluconate mouthwash, the standard product. Subject will be counseled to take 10ml of the mouthwash and rinse mouth with it for 1 minute, after brushing teeth. The frequency will be once daily at night for 30 days. The adherence shall be monitored by counting the returned of unused mouthwash bottles.
Control group
Active

Outcomes
Primary outcome [1] 329854 0
Turesky Modification of the Quigley–Hein dental plaque index
The index score ranges from 0 to 5 as follows:
0= no plaque
1= separate flecks of plaque at the cervical margin of the tooth
2= a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth
3= a band of plaque wider than 1 mm but covering less than one-third of the crown of the tooth
4= plaque covering at least one-third but less than two-thirds of the crown of the tooth
5= plaque covering two-thirds or more of the crown of the tooth
Timepoint [1] 329854 0
At time of recruitment
At 30 days post-intervention commencement
Primary outcome [2] 329855 0
Löe–Silness gingivitis index
The index score ranges from 0-4 as follows:

0= absence of inflammation
1= mild inflammation – slight change in color and little change in texture
2= moderate inflammation – moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing
3= severe inflammation – marked redness and hypertrophy. Tendency to spontaneous bleeding
Timepoint [2] 329855 0
At time of recruitment
At 30 days post-intervention commencement
Primary outcome [3] 329856 0
Sulcus Bleeding Index
The index score ranges from 0 to 5 as follows:

Score 0 – health looking papillary and marginal gingiva no bleeding on probing
Score 1 – healthy looking gingiva, bleeding on probing
Score 2 – bleeding on probing, change in color, no edema
Score 3 – bleeding on probing, change in color, slight edema
Score 4 –bleeding on probing, change in color, obvious edema
Score 5 –spontaneous bleeding, change in color, marked edema
Timepoint [3] 329856 0
At time of recruitment
At 30 days post-intervention commencement
Secondary outcome [1] 404114 0
Patient Satisfaction Level (designed specifically for this study)

This shall include 7 questions related to satisfaction to the treatment.
Each questions can be answered only in NO or YES. Satisfaction shall be based upon answering of questions. Questions shall be related to experience of participant of using the product.
Timepoint [1] 404114 0
At the end of the study
Secondary outcome [2] 404115 0
Adherence to treatment

It shall be assessed by checking number of empty or used bottles versus the unused bottles.
Timepoint [2] 404115 0
It will be conducted after completion of intervention and before commencement of final data collection.
Secondary outcome [3] 404116 0
Invitro culture sensitivity test

All subject of a group will be asked to open mouth and the investigator shall rub a cotton stick all around in the mouth and shall put it into a bottles containing normal saline. The bottles shall be mixed in a large container and shall be incubated at 37 Celsius for 24 hours. An inoculum shall be taken and shall be introduced into different petri dishes containing agar-medium for culturing of bacteria.
A drop of mouth wash under test shall be put in the medium in one location. After complete incubation of 3 days at 37 Celsius, the degree of inhibition shall be assessed to assess sensitivity.
Timepoint [3] 404116 0
Sample will be taken at time of recruitment.

Eligibility
Key inclusion criteria
1. Patient with dental plaque and gingivitis
2. Patient with at least 28 teeth
3. Patient above age of 18 years
4. Patient below age of 70 years
5. Patient capable of giving consent
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Smokers & narcotic addicts
2. Pregnant and lactating patients
3. Patients taking anti-platelets and anti-coagulant medications
4. Foreign nationals
5. Patients having other infections
6. Patients having any disorders related to blood clotting
7. Dementia

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation shall be concealed to subject through use of coded labels so only Principal Investigator will know where the subject is allocated.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The data collected shall be analyzed by SPSS. Descriptive statistics including frequencies and percentages shall be presented for nominal and scale data respectively. In inferential statistics, correlation test will be applied to assess if there is any relation with group with indices and side effects. Further regression test will be applied to check if indices and side effects are dependent on group. ANOVA both one way and two way shall be run to determine intra and inter group variations in means. Paired sample t test, independent t test and chi-square test shall be run to determine significant difference between baseline data and final data.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/06/2022
Actual
Date of last participant enrolment
Anticipated
7/06/2022
Actual
Date of last data collection
Anticipated
7/07/2022
Actual
Sample size
Target
66
Accrual to date
Final
Recruitment outside Australia
Country [1] 24396 0
Pakistan
State/province [1] 24396 0
PUNJAB

Funding & Sponsors
Funding source category [1] 310352 0
Self funded/Unfunded
Name [1] 310352 0
Dr. Mustafa Ijaz
Country [1] 310352 0
Pakistan
Primary sponsor type
Individual
Name
Dr. Malik Hassan Mehmood
Address
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University, Kotwali Rd, Faisalabad City, Punjab 38000
Country
Pakistan
Secondary sponsor category [1] 311487 0
Individual
Name [1] 311487 0
Dr. Rida Siddique
Address [1] 311487 0
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University, Kotwali Rd, Faisalabad City, Punjab 38000
Country [1] 311487 0
Pakistan

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 310008 0
Institutional Review Board, Government College University Faisalabad
Ethics committee address [1] 310008 0
Ethics committee country [1] 310008 0
Pakistan
Date submitted for ethics approval [1] 310008 0
15/12/2021
Approval date [1] 310008 0
Ethics approval number [1] 310008 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 116166 0
Dr Mustafa Ijaz
Address 116166 0
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University, Kotwali Rd, Faisalabad City, Punjab 38000
Country 116166 0
Pakistan
Phone 116166 0
+92412551354
Fax 116166 0
Email 116166 0
[email protected]
Contact person for public queries
Name 116167 0
Mustafa Ijaz
Address 116167 0
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University, Kotwali Rd, Faisalabad City, Punjab 38000
Country 116167 0
Pakistan
Phone 116167 0
+92412551354
Fax 116167 0
Email 116167 0
[email protected]
Contact person for scientific queries
Name 116168 0
Mustafa Ijaz
Address 116168 0
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University, Kotwali Rd, Faisalabad City, Punjab 38000
Country 116168 0
Pakistan
Phone 116168 0
+92412551354
Fax 116168 0
Email 116168 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
All data after de-identification shall be shared.
When will data be available (start and end dates)?
Immediately following publication, no end date
Available to whom?
anyone who wishes to access it, only researchers who provide a methodologically sound proposal at discretion of Principal Investigator
Available for what types of analyses?
Available for meta-analysis
How or where can data be obtained?
By email to Principal Investigator at [email protected]


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
14404Informed consent form    Informed consent shall be shared only as an eviden... [More Details]
14405Ethical approval    Ethical approval will be uploaded once approval is... [More Details]



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.